Bendamustine combined with rituximab induces pyroptosis to shape an "immunologically hot" tumor microenvironment in DLBCL cells via the STING pathway

ABSTRACT: Bendamustine plus rituximab (BR) therapy has demonstrated favorable clinical outcomes in the treatment of DLBCL patients who are intolerant to R-CHOP therapy. In vitro, BR therapy exhibits a synergistic cytotoxic effect on DLBCL cell lines. Mechanistically, BR induces pyroptosis in DLBCL cells by activating the cGAS-STING pathway, leading to the release of inflammatory factors and the formation of an "immunologically hot" microenvironment. Additionally, BR therapy upregulates MHC molecules on the tumor cell surface, thereby augmenting T cell activation and function.

ORGANISM(S): Homo sapiens

PROVIDER: GSE249466 | GEO | 2024/08/01

REPOSITORIES: GEO